02.02 adult art initiation gsn
DESCRIPTION
TRANSCRIPT
USAID APHIA IINAIROBI/CENTRAL
Module 2: Anti Retroviral Therapy in Adults and Adolescent
Unit 2: When to initiate Highly Active Anti Retroviral Therapy (HAART)
USAID APHIA IINAIROBI/CENTRAL
UNIT 2: Objectives
• Understand the principles and goal of successful antiretroviral therapy (ART)
• Understand the components of a Highly Active Anti Retroviral Therapy (HAART) regimen and the rationale for use of national standardized ART regimens
• Understand when ART should be initiated and who should be started on ART
• Understand drug and non-drug related considerations prior to initiating ART
USAID APHIA IINAIROBI/CENTRAL
SPIRITUAL
THE PERSON
EMOTIONAL PHYSICAL
SOCIAL
Holistic care
USAID APHIA IINAIROBI/CENTRAL
The comprehensive care team managing the patient
Spouse/partner
Other family and friends
Community services
Spiritual Care givers
Occupational therapist
Physiotherapist
Doctors Nurses
Counsellor
Nutritionist
USAID APHIA IINAIROBI/CENTRAL
ART is part of the comprehensive care of HIV infection
• Clinical care of HIV involves – Multidisplinary team effort– Counseling and continued support
• Diagnosis• Nutritional counseling• Adherence• Chronic illness with impact on lifestyle• Care of the dying and bereavement
– Management of OIs• Screening • Prophylaxis• Treatment
– Reproductive health care• Prevention and treatment of STIs• Contraception• Cervical Cytology• Pre and post natal care
– ART
USAID APHIA IINAIROBI/CENTRAL
1. Develop a treatment partnership with your patient.2. Focus on your patient’s concerns and priorities.3. Use the 5 A’s:Assess, Advise, Agree, Assist, Arrange.4. Educate patient on disease and support patient self-
management.5. Organize proactive follow-up.6. Involve peer educators and support staff in your health facility.7. Link the patient to community-based resources and support.8. Use written information—registers, Treatment Plan, treatment
cards and written information for patients—to document, monitor, and remind.
9. Work as a clinical team.10. Assure continuity of care.
USAID APHIA IINAIROBI/CENTRAL
AIM OF ART
Improve symptom free longevityby
maximal, sustainable & durablesuppression of viral replication
(<50 copies/ml)
USAID APHIA IINAIROBI/CENTRAL
Principles of ART
• Antiretroviral treatment is part of the comprehensive care of HIV infection
• Treatment should be planned and started in good time• Regular follow up and monitoring is essential • Treatment should be stopped/changed when necessary• The choice of drugs should take into account
– Efficacy– Tolerability– Dose Schedule– Affordability and availability
USAID APHIA IINAIROBI/CENTRAL
Principles of ART cont’d
• ARV drugs are associated with adverse events and drug-drug interactions
• Adherence is key to successful treatment • Treatment may fail despite patient’s and carer’s
best efforts• There should be commitment to continued support
of patient (and family)
USAID APHIA IINAIROBI/CENTRAL
Characteristics of good HAART
• Potent: should bring down viral load to an undetectable level within 3-4 months of therapy
• Acceptable regimen to maximize adherence - simple - tolerable side effects - patient commitment for life-long therapy• Reasonable options for future therapy• Affordable and sustainable
USAID APHIA IINAIROBI/CENTRAL
HAART…….Cont.
HAART does not cure HIV but halts viral replication,thus prevent further disease progression and immune system damage
USAID APHIA IINAIROBI/CENTRAL
HISTORY OF ART
1980 - 1987 - NO THERAPY1987 - 1994 - MONO THERAPY1994 - 1999 - COMBINATION THERAPY (HAART)1999 - 2002 - COMPLICATED THERAPY2002 - 2005 - SIMPLIFIED THERAPY
USAID APHIA IINAIROBI/CENTRAL
Goals of ART
• 1. Maximal suppression of HIV replication
• 2. Restoration and preservation of immune function
• 3. Improved Quality of Life• 4. Reduction of HIV related
Morbidity and Mortality
USAID APHIA IINAIROBI/CENTRAL
1. Suppression of HIV Replication
• ARVs must be taken in combination of at least 3 drugs
• Strict adherence to treatment is of the utmost importance– <95% adherence allows the rapid development of
viral resistance– Poor adherers do badly
• Fail treatment much earlier
USAID APHIA IINAIROBI/CENTRAL
2. Immune Reconstitution
• ART prevents CD4 destruction by HIV• CD4 cell count can recover • Improved function of CD4 cells• CD4 cells are central to the immune system
– So there is improved overall function of the immune system– It takes from 6 to 8 weeks for this to become evident clinically
USAID APHIA IINAIROBI/CENTRAL
3. Improvement of QOL
• Decreased hospitalizations• Decreased risk of illnesses• Increased general well-being• Reversal of weight loss • Ability to return to work
USAID APHIA IINAIROBI/CENTRAL
Take-home Messages about ART
• Not an emergency treatment– Benefits take 6 to 8 weeks– Should not be initiated while an inpatient
• Treat opportunistic infections first – OI’s cause >90% of morbidity in HIV– >90% of OI’s are simple to treat
• ART is only one part of HIV Care– All who require ART should first be on CPT first
• Optimize nutrition
USAID APHIA IINAIROBI/CENTRAL
Take-home Messages about ART
• Adherence counselling essential• Patients should be able to demonstrate an understanding of:
– Importance of strict adherence – Their ability to afford drugs long term– Life-long treatment, monthly follow-up
• The Kenyan National Guidelines should be followed– “If you don’t agree with them, campaign for a
change rather than ignoring them!”
USAID APHIA IINAIROBI/CENTRAL
Antiretroviral drugs: best practice
• Minimum combination of three drugs from at least 2 different classes drugs
– 2 NRTIs + NNRTI– 2 NRTIs + 2 PIs*– 2 NRTIs + PI
• Never use mono- or dual- therapy – Do not adequately suppress viral replication – Allow resistance to develop rapidly
• may adversely affect use of class of drugs involved
• Triple nucleoside therapy (ABC+3TC+AZT) – Best avoided especially in absence of viral load tests, treatment-
experienced– Utility mainly in some cases of treatment simplification/rare cases of drug
interactions*
USAID APHIA IINAIROBI/CENTRAL
PROTOCOL FOR ART REGIMEN
• Confirmation of HIV diagnosis• Counseling for ART• Baseline investigations • Indications of therapy• Selection of regimens• Monitoring of ART• Switching of regimens • Resistance testing
USAID APHIA IINAIROBI/CENTRAL
BASELINE INVESTIGATIONSTo Rule Out
Underlying O.Is X-ray chest Montoux test Sputum for AFB USG abdomen FNAC/Biopsy of
lymphnodes VDRL HbsAg
For Monitoring ARVHbCBCLFTRFTBlood sugarUrineStool &S. CholesterolS.TriglyceridesS. Uric acidS.CreatinineS. Lactic acidS. Amylase
Prognostic InvestigationsCD4
lymphocyte enumeration
PlasmaViral load assays
USAID APHIA IINAIROBI/CENTRAL
When to Start ART in Adults and Adolescents
Where CD4 Testing NOT available
• WHO III & IV regardless of total Lymphocyte count
• WHO II when total lymphocyte count <1200/mm3
USAID APHIA IINAIROBI/CENTRAL
When to Start ART in Adults and Adolescents
Where CD4 testing available
• WHO I& II when CD4 < 250/mm3
• WHO stage III when CD4 count < 350/mm3
• WHO stage IV irrespective of CD4 level
USAID APHIA IINAIROBI/CENTRAL
Guidance on Clinical Criteria
• In symptomatic patients with stage 3 and 4 disease CD4 is not essential for initiating treatment
The cut-off levels of CD4 count are not– A sick, deteriorating patient with a CD4 of 210 should not be
excluded from ART if otherwise able and keen to begin
– A very well, stable patient with a CD4 of 180 could reasonably opt for close follow up and deferral of ART to a later date
USAID APHIA IINAIROBI/CENTRAL
TB/HIV Co-infected Patients
• Always give TB treatment priority• All patients should be on cotrimoxazole prophylaxis• Optimum time to start ART in TB/HIV co-infected patients is
not known– Consider the risk of HIV progression if ART is delayed– Balance against risk of having to discontinue therapies because
of toxicities, side effects, paradoxical reactions or unforeseen drug/drug interactions if ART is started
USAID APHIA IINAIROBI/CENTRAL
ART and TB: When to start
CD4 Count Treatment Recommendation
CD4 <100/mm3 Start anti-TB treatmentStart ART as soon as possible
CD4 count 100-200/mm3 Start anti-TB treatmentStart ART after intensive phase
CD4 count 200-350/mm3 Start anti-TB treatmentStart ART after completion of TB treatment
CD4 count not available Start anti-TB treatmentConsider clinical status: start ART as appropriate
USAID APHIA IINAIROBI/CENTRAL
ART and TB
• ART is recommended for all patients with TB with CD4 counts < 200/mm3 and should be considered in patients with CD4 counts < 350/mm3
• In the absence of CD4 counts, ART is recommended for all patients with TB
USAID APHIA IINAIROBI/CENTRAL
Rationale Behind Standardized ARV Therapy
• Success of TB treatment program• Simplicity of prescribing• Preservation of certain ARV’s on a population
level • Simple sequencing of 1st to 2nd line• Increased efficiency in drug procurement• Cost and availability of FDC’s
USAID APHIA IINAIROBI/CENTRAL
National Standard 1st Line Regime for Adults and Adolescents
Lamivudine +
Stavudine/Zidovudine
+Nevirapine
Lamivudine+
Stavudine/Zidovudine
+Efavirenz
or
USAID APHIA IINAIROBI/CENTRAL
Standard 2nd Line Regime for Adults and Adolescents
Didanosine (ddI)+
Abacavir (ABC)+
Lopinavir/ritonavir• (LPV/r)
Tenofovir (TDF)+
Abacavir (ABC)+
Lopinavir/ritonavir(LPV/r)
or
USAID APHIA IINAIROBI/CENTRAL
For Patients on Non-standard 1st line Regimes…
1st LineD4T+ddI+NNRTI
AZT+3TC+PI
AZT+3TC+ABC
2nd LineAZT/ABC+3TC+LPV/r
NNRTI+ABC+ddI
NNRTI/LPV/r+ TDF+ d4T
USAID APHIA IINAIROBI/CENTRAL
A note on Fixed Dose Combinations (FDC’s)
• WHO Approved FDC’s are available for:– d4T/3TC/NVP– D4T/3TC– AZT/3TC
• Advantages – Decreased pill burden– Increased adherence– Mono or duo-therapy not possible– Lower cost– Simplify stock control and forcasting
• GoK has chosen these for the National roll-out
USAID APHIA IINAIROBI/CENTRAL
Pregnancy and ART
• Not a contraindication for ART• In general, best to defer to after the first trimester (after
organogenesis)• EFV contraindicated• ART greatly decreases vertical transmission• Also allows mother to remain well to care for her child• Avoid d4T and DDI together; increased risk of lactic
acidosis
USAID APHIA IINAIROBI/CENTRAL
Virological Failure and Adherence
Paterson,Swindells,Mohr. Adherence to PI therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30
>95% 82%90-95% 45%80-90% 33%70-80% 29%<70% 18%
Adherence with HAART Number with VL <500 cop/ml(% prescribed pills taken)
USAID APHIA IINAIROBI/CENTRAL
Patient Preparation
• Issue of lifelong continuous treatment
• Expected benefits
• Potential side effects of treatment and what to do
• Necessity for regular follow up
• Adherence and relation to outcome, drug resistance
• Adjusting to changes in lifestyle
• Recreational drug use
• Use of concomitant medication
• Medication not to be shared
• Point of contact if needed
USAID APHIA IINAIROBI/CENTRAL
Considerations prior to starting ART
• Logistics– Availability of ARVs
– Sustainability • Drug related
– Drug Interactions• Co-infections • Contraception• Combined toxicity Patient
factors
– Body weight• 60kg key in determining dose
of Stavudine and Didanosine• Kids
• Patient factors– Previous ART use by
patient
– Pregnancy• Not a contraindication for
ART• Effects of ARVs on
pregnant woman and fetus- largely unknown
• Delay starting ARVs until 2nd trimester
• Avoid Efavirenz during 1st trimester (and in women of child bearing potential)
USAID APHIA IINAIROBI/CENTRAL
When to Start: Early Initiation of Antiretroviral Therapy
• Benefits– Control of viral replication and mutation– Preservation of immune system – Decreased risk of selection of resistant virus– Possible decreased risk of viral transmission
• Risks– Drug-related reduction in quality of life– Greater cumulative drug-related adverse events– Possible earlier development of drug resistance– Limitation of future treatment options
USAID APHIA IINAIROBI/CENTRAL
When to Start: Delayed Initiation of Antiretroviral Therapy
• Benefits– Avoid negative effects on QOL and drug-related adverse
events– Delay development of drug resistance– Preserve future treatment options
• Risks– Possible risk of irreversible immune system destruction– Possible greater difficulty in suppressing viral replication– Greater likelihood of adverse events– Co-infections and drug interactions– Immune reconstitution– Possible increased risk of HIV transmission
USAID APHIA IINAIROBI/CENTRAL
Summary
• HAART should be started in good time• Patient understanding and acceptance for ART is
of utmost importance• ADHERENCE to ART is success to ART• National ART should be used for better
management of the patient (Easy referral from public-private-public set up)
USAID APHIA IINAIROBI/CENTRAL
THANK YOU